A decade ago researchers announced development of a cancer immunotherapy called CAR (for chimeric antigen receptor)-T, in which a patient is re-infused with their own genetically modified T cells equipped to mount a potent anti-tumour attack. Since then CAR T approaches (one of several strategies collectively known as “adoptive T cell transfer”) have made headlines
Athersys announced additional favorable data from its exploratory Phase 1/2 acute respiratory distress syndrome (ARDS) clinical trial. Dr. Geoff Bellingan, Medical Director at University College London Hospitals, described the data from the clinical trial, referred to as the MUST-ARDS trial, during his presentation today at the American Thoracic Society International Conference in Dallas, Texas, the
Source European Commission Atherosclerosis is a common, potentially serious condition caused by a build-up of fatty material in the lining of the artery walls. It can lead to coronary artery disease, stroke or kidney problems, and existing treatments tend to be only short-term fixes. In response to this public health challenge, EU-funded project THE GRAIL
In light of additional data from ongoing trials of onasemnogene abeparvovec (Zolgensma®, Novartis/AveXis), as well as the treatment’s final FDA label and just-announced launch price, the Institute for Clinical and Economic Review (ICER) today published an addendum to its Final Evidence Report on treatments for spinal muscular atrophy (SMA). Since the publication of ICER’s Final Evidence Report on
Source STAT he Food and Drug Administration on Friday approved the first gene therapy for a type of spinal muscular atrophy, a lifesaving treatment for infants that will also be the most expensive drug in the world. Known as Zolgensma, the gene therapy treats children under 2 years of age with spinal muscular atrophy, an
Source ARM Acute Myocardial Infarction Patients Treated Early With Cell Therapy Delivered With BioCardia’s HElix Endocardial Delivery System Improved in Ejection Fraction and NYHA ClassMay 23, 2019 – (BioCardia) – At 12 months, patients with Helix-delivered cell therapy experienced a 7.33 percent imprvement in ejection fraction at 12 months compared to the control group. Helix patients
Bone defects caused by various aetiologies, such as trauma, tumours, infection and congenital deformities, together with articular cartilage defects and osteochondral complex defects caused by trauma and degenerative diseases, are common clinical diseases that significantly affect the patient’s quality of life. Repair and regenerating these defects in bone and cartilage is a considerable challenge for
Researchers of the Institute of Neurophysiology and Centre for Molecular Medicine Cologne (CMMC), University of Cologne (UKK) and Leibniz Research Centre for Working Environment and Human Factors, Technical University of Dortmund (IfADo) have just published a paper in Trends in Molecular Medicine showing that hiPSC differentiation protocols theoretically offer the prospect of an unlimited supply
Wake Forest Institute for Regenerative Medicine (WFIRM) researchers have shown the feasibility of bioengineering vascularized functional renal tissues for kidney regeneration, developing a partial augmentation strategy that may be a more feasible and practical approach than creating whole organs. In the proof-of-concept study published online this month in Acta Biomaterialia journal, the scientists created a novel
York University scientists have uncovered a unique set of genes that play a role in muscle cellular gene expression and differentiation that could lead to new therapeutic targets to prevent the spread of muscle cancer. The researchers analyzed gene networks in muscle cells and found that the Smad7 and β-catenin proteins work co-operatively inside the
